Profectus Biosciences, Inc.
http://www.profectusbiosciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Profectus Biosciences, Inc.
Aurobindo's US Respiratory Filing Could Rival Teva's Qvar
Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.
Aurobindo Enters Fray For COVID-19 Vaccine
Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.
Ebola Vaccines: FDA Being ‘More Liberal’ On Accelerated Approval, Novavax Says
Advisory committee likes alternative trial designs, but says more data is needed on immune markers.
Ebola Vaccines: FDA Weighs Alternative Study Designs, Approval Pathways
As incidence of Ebola declines, advisory committee will consider alternatives to randomized controlled trials – an approach FDA had previously argued was inappropriate.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice